Toinv - In the video presentation last Thursday he said Hepa was paying for half and he would be looking for $30 to $35 million. When you look at the $200 mil and 10,000 patients versus the 3600 patients he's talking about for BoM2 the numbers all jibe. The $10 billion dollar question is will the trial being planned be underpowered yet again? The data from BoM suggests we should be fine but we have be down this road be and lost an axel.

We have an interesting few months ahead of us ... one way or the other. Having just bought a few more shares I'm hoping for just one way.

tada